Workflow
上海凯宝(300039) - 2017 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2017 was CNY 457,397,439.38, representing a 6.19% increase compared to CNY 430,746,288.07 in the same period last year[8] - Net profit attributable to shareholders was CNY 90,694,928.92, up 9.12% from CNY 83,114,086.23 year-on-year[8] - Net profit after deducting non-recurring gains and losses was CNY 93,905,679.61, a 4.84% increase from CNY 89,566,628.32 in the previous year[8] - Basic earnings per share increased to CNY 0.1100, reflecting a 9.13% rise from CNY 0.1008[8] - The company achieved operating revenue of 457.40 million CNY, a year-on-year increase of 6.19%[25] - The net profit attributable to shareholders was 90.69 million CNY, reflecting a year-on-year growth of 9.12%[25] - Operating profit for the current period was ¥110,025,360.60, compared to ¥97,418,390.26 in the previous period, indicating an increase of 12.9%[59] - Net profit for the current period was ¥90,694,928.92, up 9.5% from ¥83,114,086.23 in the previous period[60] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,654,752,071.20, a 5.02% increase from CNY 2,527,915,724.93 at the end of the previous year[8] - Total current assets increased to ¥2,052,498,761.89 from ¥1,922,946,076.24, reflecting a growth of approximately 6.9%[50] - Total liabilities increased to ¥363,746,498.28 from ¥327,605,080.93, reflecting a rise of about 11.0%[52] - The company's equity attributable to shareholders rose to ¥2,291,005,572.92 from ¥2,200,310,644.00, indicating an increase of approximately 4.1%[53] Cash Flow - The net cash flow from operating activities decreased by 15.35% to CNY 71,212,744.67 from CNY 84,122,564.37 in the previous year[8] - The net cash flow from operating activities for the first quarter was ¥71,212,744.67, a decrease of 15.5% compared to ¥84,122,564.37 in the previous year[67] - The company reported a total cash inflow from operating activities of ¥427,432,365.48, an increase of 15.6% compared to ¥369,706,238.10 in the previous year[69] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 38,692[15] - The top ten unrestricted shareholders include New Xiang City Kaiyi Industrial Co., Ltd. with 84,015,360 shares and Mu Lai'an with 61,842,450 shares[19] - The company did not conduct any agreed repurchase transactions during the reporting period[17] Research and Development - The company is focusing on R&D innovation, particularly on the safety re-evaluation of its core product, Tanreqing injection[26] - The company is conducting clinical research for new products, including Tanreqing oral solution and Tanreqing nebulized solution, to optimize product structure[27] - The company is in the process of III phase clinical research for Dinggui oil soft capsules, aimed at optimizing product structure[27] - The company is conducting clinical research on new drugs, including "Shu Feng Zhi Tong Capsule" and "Hua Dan An Shen He Ji," both in Phase III clinical trials[28] Investment and Projects - The company plans to invest a total of 126 million CNY in the construction of a new R&D building using remaining raised funds and its own funds[33] - The total amount of raised funds for the quarter is 97,375.76 million[38] - The cumulative amount of raised funds used is 93,630.99 million, with a usage ratio of 0.00% for the current period[38] - The company has invested 6,721 million in acquiring Shanghai Kaibao New Yi Pharmaceutical Co., Ltd., achieving 100% of the planned investment[39] Market and Strategy - The company is focusing on new product launches and market expansion, particularly in traditional Chinese medicine products[13] - The company is accelerating the development of new products and expanding its market coverage to enhance its competitive advantage[31] - The company is actively monitoring industry policy changes and adapting its strategies to market fluctuations[31] Risk Factors - The company faces risks from industry policy changes, including drug price reductions and the impact of new healthcare regulations[11] - The company has not disclosed any significant changes in financial data or indicators during the reporting period[23]